Italia markets closed

Revolution Medicines, Inc. (RVMD)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
38,21+0,67 (+1,78%)
Alla chiusura: 04:00PM EDT
38,21 0,00 (0,00%)
Dopo ore: 04:20PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente37,54
Aperto37,60
Denaro38,13 x 300
Domanda38,25 x 300
Min-Max giorno37,41 - 38,57
Intervallo di 52 settimane15,44 - 41,21
Volume3.722.179
Media Volume1.257.051
Capitalizzazione6,304B
Beta (mensile su 5 anni)1,45
Rapporto PE (ttm)N/D
EPS (ttm)-3,84
Prossima data utili06 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A45,55
  • GlobeNewswire

    Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

    Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations First clinical data presentation for RMC-6291, a RASG12C(ON) Inhibitor, highlights encouraging initial tolerability, safety and differentiated anti-tumor activity Investor webcast to be held Sunday, October 22 at 12:30pm Eastern Time REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Revol

  • GlobeNewswire

    Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

    Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m. Eastern REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will present new clinical data for two of its RAS(ON) Inhibitors and other in

  • GlobeNewswire

    Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

    KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers REDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, co